Objective To explore the pathogenesis of steroid-induced osteonecrosis of the femoral head(SONFH)and the mechanism of Traditional Chinese Medicine(TCM)-based prescription for"Bringing Blood Downward"targeting SONFH through the OPG/RANKL/RANK signaling pathway.Methods Fifty male SD rats were randomly divided into model group and control group.The rats in the model group were treated with LPS and methylprednisolone to build a SONFH model.After 6 weeks,two rats were randomly selected respectively from the two groups,and the SONFH model was confirmed by histomorphological examination under light microscopy.The rats in a low,medium and high dose treatment groups(group L,M,and H)were intragastrically administrated with the Prescription for"Bringing Blood Downward"at concentrations of 2.5/5/10 g/kg.While the rats in the model group and control group were intragastrically administrated with normal saline at a concentration of 5 g/(kg·d).The pathological changes and expression levels of OPG,TRAF-6,and RANKL in each group were examined 4 weeks later.Results Compared with the model group,chondrocytes and cell matrix of groups L,M and H were less reduced,osteoclastic absorption and trabecular structure were less destroyed and the cells were less adipose.The adipocyte density in the control group and each treatment group was significantly lower than that in the model group(P<0.01).In the control group,the bone marrow cavity area was smaller than that in the model group(P<0.05),but there was no significant difference between each dose treatment groups and the model group(P>0.05).The expression levels of OPG,RANKL,TRAF-6 and OPG/RANKL ratio in the control group and groups L,M and H were significantly lower than those in the control group(P<0.01).Conclusion The TCM-based prescription for"Bringing Blood Downward"works to treat SONFH byregulating the activity of osteoclasts and osteogenic differen-tiation process of osteoblasts,improving the microcirculation environment of the femoral head,and inducing the formation of trabecular bone through the OPG/RANKL/RANK signaling pathway.It functions with its multitargetsin diverse methods.

Objective To analyze the efficacy of higher pressure recompression therapy (≥70 m) in the patients with decompression sickness (DCS),who displayed poor efficacy after initial recompression.Methods Forty patients with type Ⅱ DCS who received treatment in our hospital from September 2011 to June 2018 were selected as research subjects,and were designated as the study group (n =6) and the control group (n =34),in accordance with whether or not they had received recompression therapy before admission into hospital.The DCS patients of the study group were those transferred to our hospital after initial lower pressure recompression treatment with unsatisfactory results.These patients were treated with the Air Diving DCS Recompression Treatment Table (Table 5,Oxygen Breathing) developed by the Chinese Naval Medical Research Institute,at a pressure of 70 meters and with a total oxygen breathing time of 225 minutes.The patients of the control group were those with type Ⅱ DCS patients who received initial recompression treatment in our hospital within the same time span.Delayed time,application rate and treatment efficacy in the patients of the 2 groups were analyzed statistically.Results The delayed time (14.5 ± 4.9 h) of the secondary recompression group (or the study group) was obviously longer than that of the control group(4.3 ± 3.0 h) (P ＜ 0.001),and there was statistical significance when comparisons were made between them (P ＜ 0.001).The application rate of higher pressure treatment profile in the secondary recompression group (83.3％) was higher than that of the control group (5.9％),also with statistical significance (P ＜ 0.001).The treatment efficacy of the 2 group was identical,without statistical significance (P =0.585).Conclusion The higher pressure recompression profile could effectively treat those DCS patients who showed unsatisfactory treatment effects after initial recompression.For those DCS patients with delayed treatment,proper recompression profile could also achieve satisfactory treatment outcome.With the lack of low pressure oxygen-breathing treatment profile and other supplementary treatment methods,secondary higher pressure recompression treatment should be performed as early possible,in the treatment of the patients with type Ⅱ DCS.

Objective To analyze the efficacy of higher pressure recompression therapy (≥70 m) in the patients with decompression sickness (DCS),who displayed poor efficacy after initial recompression.Methods Forty patients with type Ⅱ DCS who received treatment in our hospital from September 2011 to June 2018 were selected as research subjects,and were designated as the study group (n =6) and the control group (n =34),in accordance with whether or not they had received recompression therapy before admission into hospital.The DCS patients of the study group were those transferred to our hospital after initial lower pressure recompression treatment with unsatisfactory results.These patients were treated with the Air Diving DCS Recompression Treatment Table (Table 5,Oxygen Breathing) developed by the Chinese Naval Medical Research Institute,at a pressure of 70 meters and with a total oxygen breathing time of 225 minutes.The patients of the control group were those with type Ⅱ DCS patients who received initial recompression treatment in our hospital within the same time span.Delayed time,application rate and treatment efficacy in the patients of the 2 groups were analyzed statistically.Results The delayed time (14.5 ± 4.9 h) of the secondary recompression group (or the study group) was obviously longer than that of the control group(4.3 ± 3.0 h) (P ＜ 0.001),and there was statistical significance when comparisons were made between them (P ＜ 0.001).The application rate of higher pressure treatment profile in the secondary recompression group (83.3％) was higher than that of the control group (5.9％),also with statistical significance (P ＜ 0.001).The treatment efficacy of the 2 group was identical,without statistical significance (P =0.585).Conclusion The higher pressure recompression profile could effectively treat those DCS patients who showed unsatisfactory treatment effects after initial recompression.For those DCS patients with delayed treatment,proper recompression profile could also achieve satisfactory treatment outcome.With the lack of low pressure oxygen-breathing treatment profile and other supplementary treatment methods,secondary higher pressure recompression treatment should be performed as early possible,in the treatment of the patients with type Ⅱ DCS.

AIM: To study the effects of guava polysaccharides on blood glucose level and antioxidant activity in alloxan-induced diabetic mice. METHODS: The animal model of diabetes was established by injecting alloxan into mice abdominal cavity.The mice were divided into five groups: normal control group,diabetic model group,guava polysaccharides group I,guava polysaccharides group II,glybenclamide group.Blood glucose level was determined with blood glucose monitor 3 d and 10 d after being given polysaccharides.The mice were anaesthetized and killed on the tenth day.Activity of SOD and concentration of MDA in blood serum and liver were determined. RESULTS: Compared with diabetic model group,the blood glucose level of guava polysaccharides group I and guava polysaccharides group II significantly decreased.Activity of T-SOD in blood serum and liver significantly increased,while concentration of MDA in blood serum and liver significantly decreased. CONCLUSION: Guava polysaccharides can significantly decrease blood glucose level and improve the antioxidant activity of diabetic mice.lt is a potential hypoglycemic agent.